explore -WSS

explore

author：hotspot 2025-10-01 11:02:31 - browse：5

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： J&J to buy cancer drug developer Ambrx Biopharma

leisure time

WSS

Pope Francis asks Church to identify 21st

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

New weight loss drugs work. But how can they best be used?

Adele warns fans about throwing things at performers onstage

Videos point to link between seizures and unexplained toddler deaths

entertainment

explore

entertainment

Bright Health sells Medicare Advantage business to Molina

Former New York Mayor de Blasio and wife announce separation, but not divorce

Hollywood unions extend contract negotiations for actors

Pentagon will tighten controls on classified information after Discord leak

Medicare details structure of new drug price negotiation program

How a scoliosis diagnosis changed the life of one young dancer

Activists slam private health insurers over coverage restrictions

UCB departs biotech trade group BIO

Supreme Court strikes down use of affirmative action

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

focus

Federal weight loss drug coverage is 30 years out of date

Search warrant issued in 1996 disappearance of Kristin Smart

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

The leaders of Italy and Poland say European Union should focus on stopping migration

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

explore

hotspot

leisure time

hotspot